tirzepatide
Trade name: Mounjaro
Peptideapproved
Approved
May 13, 2022
Clinical trial activity
152 trials · 88 clinical orgs · 1 marketing orgs
Phase 1
33
Phase 2
91
Phase 3
44
Phase 4
24
Earliest trial started Jan 1, 2010 (NCT01056107)
Timeline
2010s
Indications
Approved for
Studied for
- Aging · Phase 2
- Alcohol-Induced Disorders · Phase 2
- Alcoholism · Phase 2
- Angina, Stable · Phase 4
- Arthritis, Psoriatic · Phase 4
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 2
- Bariatric Surgery · Phase 4
- Binge-Eating Disorder · Phase 2
- Breast Neoplasms · Phase 2
- Cardiovascular Diseases · Phase 2
- Colitis, Ulcerative · Phase 3
- Colorectal Neoplasms · Phase 1
- Constipation · Phase 1/Phase 2
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- COVID-19 · Phase 2
- Crohn Disease · Phase 4
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 1 · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Endocrine System Diseases · Phase 3
- Endometrial Neoplasms · Phase 2
- Fatty Liver · Early Phase 1
- Glucagon-Like Peptide 1 · Phase 2
- Glucose Metabolism Disorders · Phase 3
- Healthy Volunteers · Phase 1
- Heart Failure, Diastolic · Phase 3
- Hepatic Insufficiency · Phase 1
- HIV · Phase 2
- Hypoglycemia · Phase 1
- Inflammation · Phase 2
- Kidney Failure, Chronic · Phase 1
- Liver · Phase 1/Phase 2
- Liver Diseases · Phase 3
- Menopause · Phase 4
- Metabolic Diseases · Phase 4
- Metabolism · Phase 3
- Methamphetamine · Phase 2
- Musculoskeletal Abnormalities · Phase 3
- Non-alcoholic Fatty Liver Disease · Phase 2
- Obesity · Phase 4
- Obesity, Morbid · Phase 2/Phase 3
- Opioid-Related Disorders · Phase 2
- Osteoarthritis, Knee · Phase 4
- Osteoporosis · Phase 3
- Overweight · Phase 3
- Pharmacokinetics · Phase 3
- Prader-Willi Syndrome · Phase 4
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Prostatic Neoplasms · Phase 2
- Psoriasis · Phase 4
- Renal Insufficiency · Phase 1
- Renal Insufficiency, Chronic · Phase 2
- Sarcopenia · Phase 2
- Schizophrenia · Phase 2
- Schizophrenia Spectrum and Other Psychotic Disorders · Phase 2
- Sleep Apnea, Obstructive · Phase 3
- Sleep Apnea Syndromes · Phase 3
- Substance Abuse, Oral · Phase 2
- Weight Gain · Phase 3
- Weight Loss · Phase 2
- Wolfram Syndrome · Phase 2
Mechanism of action
GIPR agonist
GLP1R agonist
Approval history
- approvedPriority reviewMay 13, 2022
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Black box warningFirst in class
Sources
- ChEMBLCHEMBL4297839 ↗
Also known as
- 10-valyl-glp
- glucagon-like peptide (7-37), val(10)-
- glucagon-like peptide (7-37), valyl(10)-
- ly3298176
- rose-010
- rose-010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07265752 | Phase 2 | Jul 1, 2026 | Harvard University |
| NCT07179120 | Phase 2 | May 1, 2026 | Wenzhou Medical University |
| NCT07298915 | Phase 3 | Feb 28, 2026 | University of Virginia |
| NCT07191873 | Phase 4 | Feb 28, 2026 | Duke University, Eli Lilly |
| NCT07299084 | Phase 1 | Jan 31, 2026 | Eli Lilly |
| NCT07292519 | Phase 2 | Jan 15, 2026 | South West Sydney Local Health District, Sydney Local Health District, University of Sydney |
| NCT07257484 | Phase 4 | Jan 5, 2026 | Cornell University, National Center for Advancing Translational Science (NCATS) |
| NCT07284511 | Phase 2/Phase 3 (Phase 3) | Jan 5, 2026 | Breakthrough T1D, McGill University, University of Bern |
| NCT07078838 | Phase 2 | Dec 31, 2025 | National Cancer Institute (NCI), University of North Carolina at Chapel Hill |
| NCT07228741 | Phase 2 | Dec 31, 2025 | St. Jude Children's Hospital |
| NCT07247084 | Phase 4 | Dec 31, 2025 | Eli Lilly |
| NCT07065552 | Early Phase 1 (Phase 1) | Dec 31, 2025 | University of North Carolina at Chapel Hill |
| NCT07202247 | Phase 2 | Dec 8, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07046819 | Phase 2 | Dec 2, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT07095517 | Phase 1 | Dec 1, 2025 | Cancer Research UK, Harvard University, National Cancer Institute (NCI) |
| NCT06820281 | Phase 2 | Dec 1, 2025 | Garvan Institute of Medical Research, Victor Chang Cardiac Research Institute |
| NCT07220473 | Phase 2 | Nov 30, 2025 | University of Texas, Galveston |
| NCT06935838 | Phase 2 | Nov 12, 2025 | University of Hawaii |
| NCT07245771 | Phase 1/Phase 2 (Phase 2) | Nov 4, 2025 | Government of China, Ikaria, Nucleus Network Ltd |
| NCT07176663 | N/A | Nov 1, 2025 | Azad University, Shahid Beheshti University of Medical Sciences |
Showing 20 of 152 trials
Page 1 / 8
Organizations
Research & Development (88)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 80 | 73 | 4 | 2016 |
| Novo Nordisk | For profit | 5 | 5 | 2 | 2023 |
| Mayo Clinic | Academic/Hospital | 4 | 4 | 2 | 2010 |
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2025 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2025 |
| The Cleveland Clinic | Academic/Hospital | 3 | 3 | 3 | 2024 |
| Government of China | Government | 2 | 1 | 1 | 2025 |
| Nanjing Medical University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 2 | 1 | 1 | 2025 |
| Stanford University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| University of Bern | Academic/Hospital | 2 | 1 | 1 | 2024 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 2 | 2 | 2025 |
| University of Sydney | Academic/Hospital | 2 | 1 | 1 | 2024 |
| University of Texas, San Antonio | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Vanderbilt University | Academic/Hospital | 2 | 1 | 2 | 2024 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 2 | 2023 |
| American Cancer Society, Inc. | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Arrowhead Pharmaceuticals | For profit | 1 | 1 | 1 | 2024 |
| Atrium Medical Center | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Azad University | Academic/Hospital | 1 | 0 | 1 | 2025 |
88 organizations
Page 1 / 5